Forging ahead on fibromyalgia The Lancet Rheumatology ++... ++

Forging ahead on fibromyalgia The Lancet Rheumatology https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00051-2/fulltext?dgcid=raven_jbs_etoc_email Mar 2026 Volume 8Number 3e159-e232 https://www.thelancet.com/journals/lanrhe/issue/vol8no3/PIIS2665-9913(26)X2002-1 Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries Eleana Bolla, MDa ∙ Anne Grete Semb, MDb ∙ Prof Michelle Petri, MDc ∙ Prof Petros P Sfikakis, MDa ∙ Bahar Artim-Esen, MDd ∙ Gabriela Hernandez-Molina, MDe ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00257-7/abstract?dgcid=raven_jbs_etoc_feature_lanrhe Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial Prof Andrew P Cope, MDa andrew.cope@kcl.ac.uk ∙ Marianna Jasenecova, MSca ∙ Joana C Vasconcelos, MScb ∙ Sumera Qureshi, MDa ∙ Dr Karin A van Schie, PhDm ∙ Prof Andrew Filer, MDd ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00371-6/fulltext?dgcid=raven_jbs_etoc_feature_lanrhe